Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
June 02, 2018 16:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
May 16, 2018 17:01 ET
|
Jounce Therapeutics, Inc.
ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...